Ocular Therapeutix OCUL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$88.61M-37.1% | -$64.65M+6.9% | -$69.42M-2.4% | -$67.81M-5.9% | -$64.05M-32.4% | ||
| $1.28M+2.9% | $1.25M+16.7% | $1.07M+4.2% | $1.03M+4.6% | $981K+3.2% | ||
| $15.58M+37.2% | $11.36M-2.8% | $11.69M+20.8% | $9.68M-7.4% | $10.46M+45.3% | ||
| $1.38M+179% | $495K-34.7% | $758K+7.1% | $708K-50.7% | $1.44M+149% | ||
| -$4.87M— | —— | —— | $29K— | —— | ||
| -$6.3M-5,242% | -$118K— | —— | —— | -$7.17M-433% | ||
| $173K+128% | $76K-83.1% | $449K+295% | -$230K-200% | $229K-63.9% | ||
| $3.72M+375% | -$1.35M-6.4% | -$1.27M-173% | $1.73M+24,629% | $7K— | ||
| -$8.44M-488% | $2.18M-59.5% | $5.38M+89.2% | $2.84M+155% | -$5.15M-222% | ||
| $357K— | —— | -$522K+50.2% | -$1.05M+73.3% | -$3.93M-1,386% | ||
| —— | —— | —— | -$64K0.0% | -$64K-3.2% | ||
| $1.77M+333% | -$759K-18.2% | -$642K— | $0+100% | -$256K-726% | ||
| -$65.99M-21.6% | -$54.25M-6.9% | -$50.73M+8.2% | -$55.24M-23.7% | -$44.67M-13.3% | ||
| $4.66M+64.2% | $2.84M-52.6% | $5.99M+381% | $1.25M-35.6% | $1.93M+857% | ||
| -$4.66M-64.2% | -$2.84M+52.6% | -$5.99M-437% | -$1.12M+42.3% | -$1.93M-857% | ||
| $294K-90.0% | $2.94M-71.6% | $10.36M+238% | $3.07M-26.7% | $4.18M+4.9% | ||
| $294K-99.9% | $449.38M+4,239% | $10.36M-89.4% | $97.81M+2,238% | $4.18M-7.3% | ||
| -$70.36M-118% | $392.29M+946% | -$46.36M-212% | $41.45M+198% | -$42.42M— | ||
| $2.19M-2.5% | $2.24M-4.0% | $2.34M+1.3% | $2.31M+7.9% | $2.14M-35.8% | ||
| $1.38M+179% | $495K-34.7% | $758K+7.1% | $708K-50.7% | $1.44M+149% | ||
| $1.46M— | —— | -$1.45M-126% | -$641K+34.5% | -$978K— | ||
| $1.86M+367% | -$696K-26.8% | -$549K— | $0+100% | -$117K— | ||
| $1.77M+333% | -$759K-18.2% | -$642K— | $0+100% | -$256K-726% | ||
| $357K— | —— | -$522K+50.2% | -$1.05M+73.3% | -$3.93M-1,386% | ||
| $1.33M— | —— | $1.62M— | —— | $564K+1,153% | ||
| $1.77M+333% | -$759K-18.2% | -$642K— | $0+100% | -$256K-726% | ||
| $2.51M— | —— | —— | —— | —— | ||
| -$70.66M-23.8% | -$57.09M-0.7% | -$56.72M-0.4% | -$56.48M-21.2% | -$46.6M-17.6% | ||
| -$70.66M-23.8% | -$57.09M-0.7% | -$56.72M-0.4% | -$56.48M-21.2% | -$46.6M-17.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ocular Therapeutix generate?
- Ocular Therapeutix (OCUL) generated -$226.2M in operating cash flow over the trailing twelve months.
- What is Ocular Therapeutix's free cash flow?
- After $14.7M of capital expenditures, Ocular Therapeutix's free cash flow was -$240.9M over the trailing twelve months, down 62.3% year over year.
- Where does Ocular Therapeutix's cash flow data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
